Verastem, Inc.
Verastem Oncology, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on developing and commercializing novel medicines targeting RAS/MAPK pathway-driven cancers. The company's website is www.verastem.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Verastem, Inc. does
In the company’s own words
Verastem Oncology, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on developing and commercializing novel medicines targeting RAS/MAPK pathway-driven cancers. The company's website is www.verastem.com.
Verastem's lead commercial product is AVMAPKI FAKZYNJA CO-PACK, a combination therapy comprising avutometinib capsules and defactinib tablets. This product received accelerated FDA approval in May 2025 for treating adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. The company achieved net product revenue of $30.9 million during its first seven months of commercial launch in 2025. AVMAPKI FAKZYNJA CO-PACK was subsequently listed as a Category 2A recommendation in the National Comprehensive Cancer Network Clinical Practice Guidelines.
The company's pipeline includes clinical-stage programs anchored by VS-7375, a potential best-in-class oral KRAS G12D dual ON/OFF inhibitor currently in Phase 1/2 development for multiple solid tumors including pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal cancer. VS-7375 received FDA Fast Track Designation in July 2025. The company is also evaluating avutometinib combined with defactinib in the RAMP 205 trial for first-line metastatic pancreatic cancer, where the selected recommended Phase 2 dose demonstrated an 83 percent confirmed overall response rate.
Verastem's confirmatory Phase 3 trial, RAMP 301, is evaluating the combination therapy versus standard of care for recurrent low-grade serous ovarian cancer with and without KRAS mutations, with topline results expected in mid-2027. The company has established a commercial presence in the United States and is pursuing geographic expansion, including obtaining Orphan Drug Designation from the European Commission in July 2025.
The company's strategy focuses on precision targeting of RAS/MAPK pathway-driven cancers through small molecule therapeutics developed as monotherapy and combination therapies. Verastem maintains a collaboration with GenFleet Therapeutics for the development of VS-7375 and related compounds in greater China, with GenFleet having generated data in over 150 patients to date.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEEDHAM, MA
- Fiscal year end
- December
- CIK
- 1526119
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Verastem, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Verastem, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Verastem, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Verastem, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Verastem, Inc.'s last four quarterly filings that the numbers alone won't show?”